

Edinburgh, U.K. 29<sup>th</sup> August 2018

## NuCana to Participate in Citi's 13th Annual Biotech Conference

Edinburgh, United Kingdom, August 29, 2018 (GLOBE NEWSWIRE) – NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at Citi's 13th Annual Biotech Conference in Boston on September 5th and 6th, 2018.

### *About NuCana plc*

*NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.*

*Our most advanced ProTide candidates, Acelarin® and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in three clinical studies, including a Phase 1b study for patients with biliary tract cancer, a Phase 2 study for patients with ovarian cancer and a Phase 3 study for patients with pancreatic cancer. NUC-3373 is currently in a Phase 1 study for the potential treatment of a wide range of advanced solid tumors.*

*For more information, please visit: [www.nucana.com](http://www.nucana.com)*

### *Forward-Looking Statements*

*This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the initiation, timing, progress and results of clinical studies of the Company's product candidates. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology.*

*Cont'd*

Edinburgh, U.K. 29<sup>th</sup> August 2018

*Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 20-F for the year ended December 31, 2017 filed with the Securities and Exchange Commission ("SEC") on March 22, 2018, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.*

*For more information, please contact:*

NuCana plc  
Hugh S. Griffith  
Chief Executive Officer  
T: +44 131-357-1111  
E: [info@nucana.com](mailto:info@nucana.com)

Westwicke Partners  
Chris Brinzey  
T: +1 339-970-2843  
E: [chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)

RooneyPartners  
Marion Janic  
T: +1 212-223-4017  
E: [mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)